Lexeo Therapeutics, Inc. Common Stock (NASDAQ: LXEO) is a Healthcare company (Biotechnology) with a market capitalization of $261M. The Maz Rating grades it against the other companies in its sector.
Lexeo Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $3.18, Lexeo Therapeutics, Inc. Common Stock trades at 1.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -41.9%, return on invested capital of -39.3% and a free cash flow yield of -37.6%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 13.89. Over the past 52 weeks the share price ranged from $2.55 to $10.99, with a beta of 1.65.
Lexeo Therapeutics, Inc. Common Stock does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.